Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This study will determine whether CT-P6 and Herceptin are equivalent in patients with early-stage breast cancer undergoing neoadjuvant chemotherapy. Our hypothesis is that the pathologic complete response rate will be equivalent in patients treated with neoadjuvant CT-P6 or Herceptin. Patients will receive 8 cycles of neoadjuvant systemic therapy and up to 10 cycles of therapy in the adjuvant setting.
Epistemonikos ID: 7bf6096da232d30498d1753dbd9a856d5cef4808
First added on: May 11, 2024